- Home
- CROX vs STVN Comparison
CROX vs STVN Comparison
Compare CROX & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CROX | STVN |
|---|---|---|
| Founded | 1999 | 1949 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Containers/Packaging |
| Sector | Consumer Discretionary | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.9B |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CROX | STVN |
|---|---|---|
| Price | $112.33 | $21.06 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 3 |
| Target Price | ★ $99.90 | $25.67 |
| AVG Volume (30 Days) | ★ 860.4K | 367.1K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.39% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.83 | N/A |
| Revenue | ★ $4,040,647,000.00 | N/A |
| Revenue This Year | $2.01 | $9.67 |
| Revenue Next Year | $2.60 | $9.99 |
| P/E Ratio | ★ $16.27 | $27.15 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $73.21 | $12.89 |
| 52 Week High | $141.28 | $28.00 |
Technical Indicators
Market Signals| Indicator | CROX | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 28.06 | 48.70 |
| Support Level | $82.49 | $20.17 |
| Resistance Level | $113.16 | $22.00 |
| Average True Range (ATR) | 3.25 | 0.78 |
| MACD | -1.26 | -0.24 |
| Stochastic Oscillator | 0.46 | 29.36 |
Price Performance
Historical ComparisonAbout CROX Crocs Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable operating segments of the company are the Crocs Brand and the HEYDUDE Brand. The company derives maximum revenue from the Crocs brand segment.
About STVN Stevanato Group S.p.A.
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.